Selank Human Research: What the Studies Actually Show
Selank has a genuine clinical trial behind it and a history as a registered Russian medicine, but the record is narrow and sits mostly outside Western peer review. Here is the honest breakdown.
Russian clinical use
Registered medicine
Human GAD trial
Exists, Russian-only
Preclinical
Supports mechanism
Western replication
Limited
A registered anxiety medicine, studied mostly in Russia
Selank is a synthetic analog of tuftsin, developed in Russia and studied as an anxiolytic that calms without the sedation and dependence linked to benzodiazepines.
The core point: Selank has more than mechanism on its side, including an actual clinical trial in anxiety patients, but that evidence is Russian-language and largely unreplicated in the West. It belongs in the promising-but-preliminary category, weighed honestly against proven, approved options.
What has been studied, and how strong it is
A real human trial and a confirmed mechanism piece, set against thin Western replication.
-
Human, clinical
Generalized anxiety disorder trial
A Russian trial in patients with generalized anxiety disorder and neurasthenia reported anxiolytic, antiasthenic and mild stimulant effects, without the sedation seen with benzodiazepine comparators. The most directly relevant human evidence.
Zozulya et al., Zh Nevrol Psikhiatr 2008 (PMID 18454096)
-
Russian clinical use
Registered as a prescription
Selank was registered and marketed in Russia as nasal drops for anxiety, which means it went through domestic clinical evaluation and has a genuine history of medical use.
-
Mechanism
GABA, enkephalinase, BDNF
Proposed mechanisms include GABA-A modulation, inhibition of enkephalinase and effects on serotonin and BDNF. A human-serum study confirmed Selank slows the enzymes that break down enkephalins; the rest is largely animal and in-vitro.
Kost et al., Bioorg Khim 2001 (PMID 11443939)
-
The gap
Independent Western replication
The GAD trial has not been repeated at scale in Western, placebo-controlled studies, and there is no large modern trial base of the kind FDA approval would require.
A real record that has not crossed over
Like Semax, Selank carries the Russia-versus-West evidence pattern. Russian clinical and research work historically has not flowed into Western, English-language peer-reviewed journals at the same rate, for reasons of translation, differing regulatory and publication pathways, and limited cross-border exchange. That is a difference in visibility and infrastructure, not proof the underlying work was unsound.
The flip side matters too: a single Russian-language trial and a base of preclinical mechanism do not add up to the kind of evidence that justifies treating Selank like an approved anxiety medication. The honest read is a promising, better-documented-than-most peptide whose central claims still await independent confirmation.
Where Selank stands in the US
No US approval, and no compounding pathway either.
Selank is not FDA-approved and was not among the peptides in the October 2026 HHS compounding policy, so it has no draft compounding route in the US. It is sold only as a research chemical, for laboratory use, not for human consumption. See the Selank compound profile for the full picture.
Frequently asked questions
Has Selank been tested in human trials?
Yes. The most directly relevant evidence is a Russian clinical trial in patients with generalized anxiety disorder and neurasthenia, which reported anxiolytic effects alongside mild antiasthenic and stimulant effects, without the sedation typically seen with benzodiazepine comparators. Selank was also registered and marketed in Russia as a prescription nasal spray for anxiety.
How strong is the evidence?
It is real but narrow. The GAD trial is a genuine human study, but it was published in a Russian-language journal and has not been independently replicated in Western, placebo-controlled trials at scale. Most of the mechanistic work on GABA, serotonin turnover and BDNF comes from animal and in-vitro research. Weigh the evidence as preliminary relative to established, FDA-approved anxiolytics.
How does Selank work?
Its calming effect is attributed to several pathways rather than one receptor: positive modulation of GABA-A receptors, inhibition of enkephalinase (the enzyme that breaks down the body's own calming enkephalin peptides), effects on serotonin metabolism and increased BDNF expression. A study in human serum confirmed the enkephalinase-inhibition piece; the rest is largely preclinical.
Is Selank better than benzodiazepines?
The interesting claim from the Russian work is anxiolytic effect without the sedation, motor impairment or dependence potential of benzodiazepines. But that comparison rests on a much smaller and less independently replicated evidence base, while benzodiazepines have a large, scrutinized record and FDA approval. It is a promising profile, not a proven head-to-head win.
Is Selank FDA-approved?
No. Selank is not FDA-approved and was not reviewed in the 2026 FDA peptide compounding process, so unlike some peptides it has no draft compounding pathway in the US. It was a registered prescription in Russia, but that does not carry over. In the US it is sold only as a research chemical, for laboratory use, not for human consumption.
How does Selank compare to Semax?
They are built from different parent molecules and studied for different jobs: Selank from tuftsin for calm and mood, Semax from an ACTH fragment for focus and cognition. Both are Russian neuropeptides with the same Russia-versus-West evidence pattern, and both influence BDNF, but they are not interchangeable.
Track your protocol with the evidence in view
Log doses, anxiety and mood in one place, and judge a compound like this honestly over time. Free.
Sources
- Zozulya AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID 18454096
- Kost NV, Sokolov OI, Gabaeva MV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorg Khim. 2001;27(3):180-183. PMID 11443939
This content is for informational purposes only and is not medical advice. Selank is not FDA-approved in the United States and was not included in the October 2026 HHS peptide compounding policy. Its clinical evidence is largely Russian and not independently replicated at scale. If you take medication for anxiety, do not change it based on this page. Research-grade Selank is sold for laboratory use only, not for human consumption. Always consult a qualified healthcare provider.